ECR_2016

Affirm™ Prone Biopsy System ADS-01472-EN-INT-001 © 2016 Hologic, Inc. All rights reserved. Hologic, 3D, Affirm, Multicare, and associated logos are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please email info@hologic.com Experience exceptional 2D and 3D™ biopsy imaging. Fast and easy access to challenging lesion locations. Significantly improved breast biopsy workflow*. *Compared to MultiCare® Platinum To find out more, visit us at ECR on our booth #318 AffirmProne-ECR_final.indd 1 8/02/2016 17:00:46 www.healthcare-in-europe.com 21 EH @ ECR ndards ography fusion ed by contrast nd 3-D mammography fusion • Distance between 2 slices: 0.1 to 8.7 mm • Acquisition time: 1 to 4 seconds • Region of interest height range: 0 to 30 cm • Reconstruction time < 5 seconds The acquisition parameters, adjustable for the anatomical body part, offer the best image quality at low dose, Stephanix adds. ‘After the reconstruction, you will have the possibility to navigate into the volume, or to decompile the acqui- sition and extract the most interest- ing slices. Moreover, to reinforce the 3-D impression, the software of the D2RS makes it possible to browse into the volume in coronal or oblique. ‘With these pieces of information, we can conclude that tomosynthesis on D2RS redefines the remote con- trolled table standards and opens new field of investigation.’ three image sets into a single co- registered study. This image set from an iodine contrast mammography study was acquired under a single breast com- pression. The lesion pointed to with the straight arrow can be identified with the 2-D image (left), although the tomosynthesis slice (centre) shows the distortion associated with the lesion more clearly, and there is also iodine contrast uptake in the lesion in the contrast image (right). The lesion pointed to with the curved arrow has strong iodine uptake, but this cannot be identi- fied easily in the dense areas of the non-contrast mammographic image seen here. In this unique study, the 2-D con- trast image can identify potential lesions based on their physiological state, which can cause increased contrast agent uptake. The standard 2-D and 3-D Mammography images can then be reviewed for morpho- logical information. Landmarks from the mammog- raphy images are also helpful for follow-up tomosynthesis guided biopsy procedures. Prof. Christiane Kuhl, University Hospital Aachen and Scientific Coordinator of the project The project’s ambition is to devel- op a radiofrequency coil that can be connected to any regular clini- cal MR scanner and transform the device into a high-resolution PET/ MRI hybrid system, which can be used to identify even the smallest breast cancer foci and better char- acterize the cancer as well as its response to therapy. Patients will also benefit as the radiation dose of the new technol- ogy will, in contrast to other PET- MRI examinations, be comparable to a regular digital mammogram. The HYPMED approach is also likely to be transferrable to other clini- cal applications, such as prostate cancer detection and hybrid cardiac imaging. proves r diagnoses oping a ground-breaking imaging st cancer and a better, more personalised, AffirmProne-ECR_final.indd 18/02/201617:00:46

Pages Overview